The Lancet
Издатель: Elsevier · ISSN 0140-6736 · 79 статей
- The Lancet Group's guidance on reporting disability: make link to the ICF explicit
- Defining success in kidney xenotransplantation
- Defining success in kidney xenotransplantation – Authors' reply
- Remibrutinib versus teriflunomide in relapsing multiple sclerosis (REMODEL-1 and REMODEL-2): two randomised, phase 3 trials
- Migraine
- Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China
- Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial
- Izalontamab brengitecan for HR+/HER2– breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial
- Irritable bowel syndrome and related disorders of gut–brain interaction
- Foodborne disease outbreaks in the USA and the need for prevention
- Long-term outcomes after percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting for left main coronary artery disease: a prospective analysis of the multicentre IRIS-MAIN registry
- Climate–health actions: global scale-up yields economic and fiscal benefits
- Retinoblastoma
- Preparing for responsive management versus renal dialysis in older people living with kidney failure and frailty or multimorbidity in the UK (Prepare for Kidney Care): a two-arm, superiority, parallel-group, open-label, pragmatic, phase 3, individually randomised controlled trial
- Left main coronary artery disease: PCI or CABG for revascularisation strategy
- Inclusion of pregnant and lactating women in the Tumaini vaccine efficacy trial: a landmark advance
- Eating disorders
- Vertigo, multifocal brain lesions, and a diagnostic clue on the skin
- Preparing for dialysis when dialysis might never begin?
- Cangrelor versus crushed ticagrelor in acute myocardial infarction complicated by cardiogenic shock (DAPT-SHOCK-AMI): a randomised, double-blind trial
- Natural ligand-based CAR T-cell therapy targeting BCMA and TACI for relapsed or refractory multiple myeloma (TriPRIL): a non-randomised, phase 1, first-in-human trial
- APRIL-based CAR T-cell targeting of BCMA and TACI in multiple myeloma
- Climate change and health: 10 years on, what next?
- Faster troponin, same time in the emergency department: what is next for acute coronary syndrome assessment?
- Multiple standards of care in non-small-cell lung cancer after EGFR-TKI therapy: progress, fragmentation, or inevitability?
- Beyond the models: addressing the catastrophic health threats facing humanity requires a holistic approach
- Global health reform is missing a generation
- Offline: China bids to lead in global health
- Global Fund appoints Mark Dybul as head
- India to cap the cost of 137 cancer drugs